Clinical Trial Update: Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing pharmacokinetics, safety, and tolerability of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate in HIV-1–infected chi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Doravirine (MK-1439) (doravirine)
• Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate (doravirine/lamivudine/tenofovir disoproxil fumarate)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-02